Improving outcomes with checkpoint blockade in non-Hodgkin lymphoma

Clin Adv Hematol Oncol. 2020 May;18(5):273-275.

Author

Affiliation

¹ Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, New York.

PMID: 32628655

No abstract available

Publication types

Interview

MeSH terms

Clinical Trials as Topic
Drug Resistance, Neoplasm
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use*
Immunotherapy
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / immunology
Lymphoma, Non-Hodgkin / therapy
Treatment Outcome

Substances

Immune Checkpoint Inhibitors